JP2011102299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011102299A5 JP2011102299A5 JP2010262852A JP2010262852A JP2011102299A5 JP 2011102299 A5 JP2011102299 A5 JP 2011102299A5 JP 2010262852 A JP2010262852 A JP 2010262852A JP 2010262852 A JP2010262852 A JP 2010262852A JP 2011102299 A5 JP2011102299 A5 JP 2011102299A5
- Authority
- JP
- Japan
- Prior art keywords
- oligopeptide
- composition according
- positive
- ability
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010038807 Oligopeptides Proteins 0.000 claims 25
- 102000015636 Oligopeptides Human genes 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 16
- 239000000725 suspension Substances 0.000 claims 8
- 102100037850 Interferon gamma Human genes 0.000 claims 7
- 108010074328 Interferon-gamma Proteins 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 230000004044 response Effects 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 238000006243 chemical reaction Methods 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 239000006228 supernatant Substances 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 101150079015 esxB gene Proteins 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 231100000331 toxic Toxicity 0.000 claims 4
- 230000002588 toxic effect Effects 0.000 claims 4
- 239000003981 vehicle Substances 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 210000005087 mononuclear cell Anatomy 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- -1 ESAT6 T cell epitope Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical group [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 1
- ZLDPNFYTUDQDMJ-UHFFFAOYSA-N n-octadecyloctadecan-1-amine;hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC ZLDPNFYTUDQDMJ-UHFFFAOYSA-N 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901020 | 1999-07-13 | ||
| DKPA199901020 | 1999-07-13 | ||
| US14401199P | 1999-07-15 | 1999-07-15 | |
| US60/144,011 | 1999-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001509760A Division JP5010079B2 (ja) | 1999-07-13 | 2000-07-13 | マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011102299A JP2011102299A (ja) | 2011-05-26 |
| JP2011102299A5 true JP2011102299A5 (enExample) | 2012-06-07 |
| JP5075969B2 JP5075969B2 (ja) | 2012-11-21 |
Family
ID=44192802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010262852A Expired - Fee Related JP5075969B2 (ja) | 1999-07-13 | 2010-11-25 | マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5075969B2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10641770B2 (en) * | 2013-12-16 | 2020-05-05 | Statens Serum Institut | Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis |
| CN120192426B (zh) * | 2025-03-04 | 2025-11-11 | 江西澄实生物科技有限公司 | 一种预防沙门氏菌感染的疫苗及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555653B2 (en) * | 1997-05-20 | 2003-04-29 | Corixa Corporation | Compounds for diagnosis of tuberculosis and methods for their use |
-
2010
- 2010-11-25 JP JP2010262852A patent/JP5075969B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4764445B2 (ja) | 結核の免疫治療および診断のための化合物およびそれらの使用方法 | |
| AU2008224343B2 (en) | Tuberculosis vaccine and diagnostics based on the Mycobacterium tuberculosis esat-6 gene family | |
| EP1523331A2 (en) | Therapeutic tb vaccine | |
| WO2001079274A2 (en) | Tuberculosis antigens and methods of use thereof | |
| CN101294964A (zh) | 一种检测活动性结核病和结核潜伏感染的试剂和方法 | |
| JP2001515359A5 (enExample) | ||
| CN107110862B (zh) | 结核分枝杆菌蛋白 | |
| JP2003510018A5 (enExample) | ||
| Roche et al. | Human T‐cell epitopes on the Mycobacterium tuberculosis secreted protein MPT64 | |
| WO2005061534A2 (en) | Improved tuberculosis vaccines | |
| US7658929B2 (en) | Immunogenic glycopeptides, screening, preparation and uses | |
| US6596281B1 (en) | Mycobacterium tuberculosis specific proteins and genes, mixtures of antigens and uses thereof | |
| WO1991014448A1 (en) | New proteins, peptides and corresponding dna or rna sequences and probes useful for diagnosing tuberculosis | |
| CN106248934A (zh) | 结核分枝杆菌抗原蛋白Rv0446c及其T细胞表位肽的应用 | |
| JP2011102299A5 (enExample) | ||
| US7820142B2 (en) | Immunogenic glycopeptides, screening, preparation and uses | |
| KR20160097325A (ko) | 결핵의 개선된 생체내 또는 시험관내 세포-매개 면역학적 진단을 위한 진단 시약 | |
| CN106405107A (zh) | 结核分枝杆菌抗原蛋白Rv2941及其T细胞表位肽的应用 | |
| CN107530414B (zh) | 区分活动性结核病和潜伏结核感染的结核分枝杆菌抗原及其应用 | |
| AU2012202486B2 (en) | Tuberculosis vaccine and diagnostics based on the Mycobacterium tuberculosis esat-6 gene family | |
| CN106442983B (zh) | 结核分枝杆菌抗原蛋白Rv3793及其T细胞表位肽的应用 | |
| US20080293620A1 (en) | Immunogenic Glycopeptides for Diagnosing Pathogenic Microorganisms Infections |